Sales of Eisai's Lenvima more than double in first quarter

Headline results for the first quarter:


JPY 154 billion ($1.4 billion)



JPY 22.1 billion ($203 million)


Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

Eisai attributed revenue growth in the quarter to significantly higher sales of Lenvima, which led growth in China and the Americas. The company noted that growth absorbed the impact of the sale of its generic pharmaceutical subsidiary in April, as well as decreased revenue on the account of the sale of marketing rights to certain products in the same period of last year.

Other results:

  • Lenvima: JPY 24.8 billion ($228 million), +108.8%, with the hepatocellular carcinoma indication driving "rapid growth "in the US
  • Halaven: JPY 10.9 billion ($100 million), +6.7%
  • Fycompa: JPY 6 billion ($55 million), +31.1%
  • Belviq: JPY 1.8 billion ($17 million), +83.2%
  • Japanese revenue: JPY 65.4 billion ($603 million), -19.5%
  • Americas revenue: JPY 29.6 billion ($273 million), +36.4%
  • China revenue: JPY 22.1 billion ($204 million), +40.3%
  • EMEA revenue: JPY 13.7 billion ($126 million), -2.1%
  • Asia and Latin America revenue: JPY 12.6 billion ($116 million), +0.7%

Looking ahead:

Eisai reaffirmed that it expects sales in fiscal year 2019 of JPY 680 billion ($6.3 billion), representing year-on-year growth of 5.8%, with profit forecast to increase 9% to JPY 72.5 billion yen ($668 million).

Pipeline update:

The company recently disclosed that a subject who took part in a Phase I study of E2082 died after completing dosing of the experimental antiepileptic drug. Eisai said Wednesday that all studies of the AMPA receptor antagonist in Japan and the US have been suspended.

To read more Top Story articles, click here.